The anti-leukemic drug nilotinib inhibits metastatic properties of colorectal cancer cells by targeting the receptor tyrosine kinase DDR1. (July 2016) - Tosti, P.; Leroy, C.; Jeitany, M.; Simon, V.; Bonenfant, D.; Thouennon, L.; Elmessaoudi, S.; Mollevi, C.; Thierry, A.; Martineau, P.; Robert, B.; Sirvent, A.; et al.